Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials-Reference-Cited by-同舟云学术

Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials

Published:1998-01 Issue:6 Volume:27 Page:1363-1378
ISSN:0361-0926
Container-title:Communications in Statistics - Theory and Methods
language:en
Short-container-title:Communications in Statistics - Theory and Methods

Author:

Timothy Chen T.,Simon Richard M.,Kom Edward L.,Anderson Stewart J.,Lindblad Anne S.,Wieand Harry Sam,Douglass Harold O.,Fisher Bernard,Michael Hamilton J.,Friedman Michael A.

Publisher

Informa UK Limited

Subject

Statistics and Probability

Link

http://www.tandfonline.com/doi/pdf/10.1080/03610929808832163

Reference26 articles.

1. Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer

2. Postoperative Adjuvant Chemotherapy or Radiation Therapy for Rectal Cancer: Results From NSABP Protocol R-011

3. A Two-Stage Procedure for Survival Studies with Surrogate Endpoints

4. Point 2: If Not Now, When?

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving efficiency in clinical trials using auxiliary information: Application of a multi-state cure model;Biometrics;2015-01-13

2. Endpoints in lung cancer trials: today’s challenges for clinical statistics;memo - Magazine of European Medical Oncology;2013-05-08

3. Accommodating missingness when assessing surrogacy via principal stratification;Clinical Trials;2013-04-03

4. Missing Data in Principal Surrogacy Settings;Springer Proceedings in Mathematics & Statistics;2013

5. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced no(n)small-cell lung cancer?;TRANSL LUNG CANCER R;2012